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The ﬁve membered heterocycles, particularly pyrazoles, isoxaz-
oles and 1,3,4-thiadiazoles are the primary skeletons of a large
number of compounds produced by nature and play a vital
role in pharmacological chemistry (Bhat et al., 2011;
Kritsanida et al., 2002). Pyrazole framework plays an essentialrole in biologically active compounds and therefore represents
an interesting template for combinatorial as well as medicinal
chemists (Foks et al., 2005; Gilbert et al., 2006; Liu et al., 2008;
Shamroukh et al., 2007). One of the most important methods
used for the synthesis of pyrazole derivatives is 1,3-dipolar
cycloaddition utilizing diazomethane, nitrile imine to activated
oleﬁns or [2+3] cyclocondensation of a,b-unsaturated ketones
with hydrazine hydrate (Wen et al., 2011). Using the dipolar
cycloadditions for the synthesis of heterocycles the regiochem-
istry can be also controlled (Bonini et al., 2009; Chandanshive
et al., 2010). The pyrazoles are also reported by the nucleo-
philic attack of hydrazines to chromones, ﬂavones or isoxaz-
oles (Levai et al., 2006; Sviridov et al., 2007). The isoxazoles
besides being potential pharmaceutical agents are also
precursors to useful intermediates such as c-amino alcohols
948 M.R. Guda et al.and b-hydroxy ketones (Kozikowski, 1984). The 1,3-dipolar
cycloaddition of nitrile oxides to alkynes is the most direct
and frequently used approach for the synthesis of isoxazoles
(Dadiboyena et al., 2007; Jawalekar et al., 2011; Sanders
et al., 2011). Apart from these, 1,3,4-thiadiazole constitutes
the active part of several biologically active compounds includ-
ing antibacterial (Foroumadi et al., 2003; Karaku and Rollas,
2002; Thomasco et al., 2003), antimycotic (Dogan et al., 2002;
Mamolo et al., 1996) and anti-inﬂammatory activities (Palaska
et al., 2002; Santagati et al., 1994; Schenone et al., 2006). The
common method for the preparation of 1,3,4-thiadiazoles
involves the reaction of aldehydes, hydrazine hydrate and ele-
mental sulfur under conventional and microwave conditions
(Mazzone et al., 1983; Mounim et al., 2005). Thionation of
dibenzoylhydrazines using Lawesson’s reagent or Phosphorus
pentasulﬁde followed by cyclization and dehydrosulfurization
is also one of the methods to produce 1,3,4-thiadiazoles
(Gierczyk and Zalas, 2005; Kiryanov et al., 2001). In addition,
the cyclization of 1,2-diacylhydrazine or its thia analogs in the
presence of a coupling agent such as SOCl2 or POCl3 and a
strong mineral acid also resulted in 1,3,4-thiadiazoles (Borg
et al., 1995; Mavrova et al., 2009; Sun et al., 2001; Xu et al.,
1998). The other important route is via exchange of oxygen
atom in 1,3,4-oxadiazole to sulfur using thiourea and tetra-
phosphorus decasulﬁde (Padmaja et al., 2012; Linganna and
Rai, 1998). In fact, we have been continuously focusing on
the synthesis of a variety of bis heterocycles held by different
pharmacophoric units (Padmaja et al., 2011a,b; Padmavathi
et al., 2008, 2009, 2011; Reddy et al., 2013). Our successful
efforts in this direction made us to design molecules having
pyrazole and isoxazole moieties in combination with 1,3,4-
thiadaizoles.
2. Experimental
2.1. Chemistry
Melting points were determined in open capillaries on a
Mel-Temp apparatus and are uncorrected. The purity of the
compounds was checked by TLC (silica gel H, BDH, EtOAc/
hexane, 1:3). The IR spectra were recorded on a ThermoNicolet
IR 200 FT-IR spectrometer as KBr pellets and the wave num-
bers are given in cm1. The 1H NMR spectra were recorded
in DMSO-d6 on a Bruker-400 spectrometer (400 MHz). The
13CNMR spectra were recorded in DMSO-d6 on a Bruker spec-
trometer operating at 100 MHz. All chemical shifts are reported
in d (ppm) using TMS as an internal standard. The mass spectra
were recorded on Jeol JMS-D 300 and Finnigan Mat 1210 B at
70 eV with an emission current of 100 lA. The microanalyses
were performed on a Perkin–Elmer 240C elemental analyzer.
The 2-((arylsulfonyl)aminosulfonyl)acetohydrazide (1) and
Z-styrylsulfonylacetic acid (2) were prepared by the literature
procedure (Reddy et al., 2013).
2.2. Typical one-pot procedure for the synthesis of 2-
(((arylsulfonyl)amino-sulfonyl)methyl)-5-[Z-(styrylsulfonyl)
methyl]-1,3,4-thiadiazole 3a–c
To a mixture of 2-((arylsulfonyl)aminosulfonyl)acetohydrazide
(1) (1.0 mmol), Z-styrylsulfonylacetic acid (2) (1.0 mmol) and
Phosphorus pentasulﬁde (P2S5) (0.66 g, 1.5 mmol) in ethylacetate (EtOAc) (5 mL), triethylamine (TEA) (0.34 mL,
2.5 mmol) followed by Propylphosphonic anhydride (T3P)
(0.36 mL, 1.2 mmol) in EtOAc (3 mL) was added dropwise
under nitrogen atmosphere and heated to 60 C for 5–7 h.
Then, the reaction mixture was cooled, poured into ice-water
and extracted with EtOAc. The combined organic phase was
washed successively with saturated sodium hydrogen carbon-
ate solution and brine. The organic phase was dried (an.
MgSO4) and the solvent was removed under reduced pressure.
The resultant residue was puriﬁed by column chromatography
(silica gel, 60–120 mesh) using hexane/EtOAc (6:1) as eluent.
Method A: The compound 5 (1.0 mmol), Lawesson’s
reagent (LR) (0.60 g, 1.5 mmol) and EtOAc (5 mL) were
reﬂuxed for 8–12 h at 65 C. After completion of the reaction,
the solvent was evaporated under vacuum and the resultant
semi-solid was chromatographed on silica gel (60–120 mesh)
using EtOAc/hexane (7:3) as eluent to afford pure product.
Method B: To a solution of compound 5 (1.0 mmol) in
EtOAc (10 mL), LR (0.60 g, 1.5 mmol), TEA (0.34 mL,
2.5 mmol), T3P (0.36 mL, 1.2 mmol) in EtOAc (7 mL) was
added dropwise. The reaction mixture was heated to 55 C
for 4–6 h, cooled and poured into ice-water. The separated
solid was extracted with dichloromethane. The solvent was
removed in vacuo. The resultant residue was puriﬁed by col-
umn chromatography (silica gel, 60–120 mesh) using hexane/
EtOAc (4:1) as eluent.
2.2.1. 2-(((Phenylsulfonyl)aminosulfonyl)methyl)-5-
[Z-(styrylsulfonyl)methyl]-1,3,4-thiadiazole (3a)
Yield 39% (0.19 g, One-step method), 55% (0.26 g, Method
A), 85% (0.41 g, Method B) as a white solid. M.p. 157–
159 C. IR (KBr): m= 3225 (NH), 1632 (C‚C), 1570
(C‚N), 1319, 1151 (SO2) cm
1. 1H NMR (DMSO-d6):
d= 4.74 (s, 2H, CH2-(C-5)), 5.02 (s, 2H, CH2-(C-2)), 6.56
(d, 1H, HB, J= 9.4 Hz), 7.14–7.72 (m, 11H, HA, ArH),
10.26 (bs, 1H, NH) ppm. 13C NMR (DMSO-d6): d= 43.2
(CH2-(C-5)), 48.2 (CH2-(C-2)), 121.2 (C-HB), 123.1, 123.7,
124.2, 125.6, 127.8, 128.4, 129.2, 130.4 (ArC), 140.1 (C-HA),
155.3 (C-5), 157.4 (C-2) ppm. MS (m/z): 499.61 (M+Æ). Anal.
Calcd. for C18H17N3O6S4: C 43.27, H 3.43, N 8.41; found C
43.51, H 3.58, N 8.76.
2.2.2. 2-(((4-Methylphenylsulfonyl)aminosulfonyl)methyl)-5-
[Z-(4-methylstyryl-sulfonyl)methyl]-1,3,4-thiadiazole, (3b)
Yield 36% (0.18 g, One-step method), 52% (0.27 g, Method A),
90% (0.46 g, Method B) as a white solid. M.p. 135–137 C. IR
(KBr): m= 3220 (NH), 1627 (C‚C), 1562 (C‚N), 1305, 1145
(SO2) cm
1. 1H NMR (DMSO-d6): d= 2.16 and 2.24 (s, 6 H,
Ar–CH3), 4.62 (s, 2H, CH2-(C-5)), 4.94 (s, 2H, CH2-(C-2)),
6.52 (d, 1H, HB, J= 9.2 Hz), 7.10–7.56 (m, 9 H, HA, ArH),
10.14 (bs, 1H, NH) ppm. 13C NMR (DMSO-d6): d= 21.5
and 21.7 (Ar–CH3), 42.4 (CH2-(C-5)), 47.3 (CH2-(C-2)), 120.2
(C-HB), 122.1, 123.4, 124.2, 124.9, 125.5, 126.9, 127.5, 128.6
(ArC), 136.4 (C-HA), 152.2 (C-5), 154.6 (C-2) ppm. MS (m/z):
527.67 (M+Æ). Anal. Calcd. for C20H21N3O6S4: C 45.52, H
4.01, N 7.96; found C 45.67, H 4.29, N 7.91.
2.2.3. 2-(((4-Chlorophenylsulfonyl)aminosulfonyl)methyl)-
5-[Z-(4-chlorostyryl-sulfonyl)methyl]-1,3,4-thiadiazole, (3c)
Yield 38% (0.21 g, One-step method), 49% (0.27 g, Method
A), 88% (0.49 g, Method B) as a white solid. M.p. 171–
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1324, 1158 (SO2) cm
1. 1H NMR (DMSO-d6): d= 4.90 (s, 2H,
CH2-(C-5)), 5.12 (s, 2H, CH2-(C-2)), 6.61 (d, 1H, HB,
J= 9.6 Hz), 7.19–7.84 (m, 9 H, HA, ArH), 10.35 (bs, 1H,
NH) ppm. 13C NMR (DMSO-d6): d= 46.6 (CH2-(C-5)),
49.8 (CH2-(C-2)), 122.4 (C-HB), 126.2, 127.6, 128.4, 129.7,
130.2, 132.6, 133.8, 135.4 (ArC), 143.6 (C-HA), 157.4 (C-5),
159.2 (C-2) ppm. MS (m/z): 568.51 (M+Æ). Anal. Calcd. for
C18H15Cl2N3O6S4: C 38.02, H 2.65, N 7.39; found C 38.41,
H 2.84, N 7.70.
2.3. Typical procedure for the synthesis of N0-(2-((arylsulfonyl)
aminosulfonyl)acetyl)-2-(styrylsulfonyl)acetohydrazide 5a–c
The Z-styrylsulfonylacetic acid (2) (1.0 mmol) was dissolved in
dry N,N-Dimethylformamide (DMF) (10 mL). To this, O-(7-
Azabenzotriazole-1-yl)-N,N,N0,N0-tetramethyluroniumhexa-
ﬂuorophosphate (HATU), (0.38 g, 1.0 mmol) was added at
room temperature and stirred for 10 min. Then 2-((arylsulfo-
nyl)aminosulfonyl)acetohydrazide (1) (2.0 mmol) was added
and stirred for 20 min followed by N,N-Diisopropylethylamine
(DIPEA) (0.52 mL, 3.0 mmol) via syringe. The reaction mix-
ture was further stirred for 22–25 h and then saturated solution
of sodium chloride was added. The mixture was cooled to 4 C
and the separated precipitate was isolated by vacuum ﬁltration
over sintered glass, washed with deionized water and recrystal-
lized from 2-propanol.2.3.1. N0-(2-((Phenylsulfonyl)aminosulfonyl)acetyl)-
2-(styrylsulfonyl)acetohydrazi-de (5a)
Yield 94% as a white solid (0.47 g). M.p. 149–151 C. IR
(KBr): m= 3264 (NH), 1682 (C‚O), 1618 (C‚C), 1316,
1154 (SO2) cm
1. 1H NMR (DMSO-d6): d= 5.30 (s, 2H,
CH2–CONH), 5.46 (s, 2H, CH2–SO2NH), 6.84 (d, 1H, HB,
J= 9.7 Hz), 7.41–7.94 (m, 11H, HA, ArH), 8.24 (bs, 1H, CH2
CO–NH), 8.82 (bs, 1H, NH–COCH2), 10.44 (bs, 1H, NH–SO2Ar)
ppm. 13C NMR (DMSO-d6): d= 51.8 (CH2–SO2NH), 53.4
(CH2–CONH), 125.2 (C-HB), 125.7, 126.6, 127.4, 128.8,
130.2, 131.5, 132.7, 133.8 (ArC), 137.2 (C-HA), 168.4 (NH–
CO), 170.2 (CO–NH) ppm. MS (m/z): 501.56 (M+Æ). Anal.
Calcd. for C18H19N3O8S3: C 43.11, H 3.82, N 8.38; found C
43.59, H 3.99, N 8.64.2.3.2. N0-(2-((4-Methylphenylphenylsulfonyl)aminosulfonyl)
acetyl)-2-(4-methyl-styrylsulfonyl)acetohydrazide (5b)
Yield 90% as a white solid (0.46 g). M.p. 121–123 C. IR
(KBr): m= 3256 (NH), 1676 (C‚O), 1610 (C‚C), 1312,
1148 (SO2) cm
1. 1H NMR (DMSO-d6): d= 2.41 and 2.54
(s, 6 H, Ar–CH3), 5.27 (s, 2H, CH2–CONH), 5.40 (s, 2H,
CH2–SO2NH), 6.79 (d, 1H, HB, J= 9.6 Hz), 7.32–7.92 (m, 9
H, HA, ArH), 7.98 (bs, 1H, CH2CO–NH), 8.75 (bs, 1H,
NH–COCH2), 10.46 (bs, 1H, NH–SO2Ar) ppm.
13C NMR
(DMSO-d6): d= 22.6 and 23.8 (Ar–CH3), 50.2 (CH2–SO2NH),
52.6 (CH2–CONH), 124.3 (C-HB), 124.6, 125.5, 126.2,
127.5, 128.4, 130.1, 131.3, 132.6 (ArC), 136.8 (C-HA), 165.9
(NH–CO), 169.4 (CO–NH) ppm. MS (m/z): 529.61 (M+Æ).
Anal. Calcd. for C20H23N3O8S3: C 45.36, H 4.38, N 7.93;
found C 45.41, H 4.49, N 7.98.2.3.3. N0-(2-((4-Chlorophenylphenylsulfonyl)aminosulfonyl)
acetyl)-2-(4-chloro-styrylsulfonyl)acetohydrazide (5c)
Yield 92% as a white solid (0.52 g). M.p. 162–164 C. IR
(KBr): m= 3276 (NH), 1694 (C‚O), 1621 (C‚C), 1321,
1159 (SO2) cm
1. 1H NMR (DMSO-d6): d= 5.34 (s, 2H,
CH2–CONH), 5.52 (s, 2H, CH2–SO2NH), 6.92 (d, 1H, HB,
J= 9.7 Hz), 7.46–7.98 (m, 9 H, HA, ArH), 8.38 (bs, 1H,
CH2CO–NH), 8.85 (bs, 1H, NH–COCH2), 10.49 (bs, 1H,
NH–SO2Ar) ppm.
13C NMR (DMSO-d6): d= 52.4 (CH2–
SO2NH), 54.8 (CH2–CONH), 125.8 (C-HB), 126.4, 127.2,
128.7, 129.6, 130.4, 131.2, 133.4, 134.1 (ArC), 138.1 (C-HA),
168.9 (NH–CO), 170.8 (CO–NH) ppm. MS (m/z): 570.45
(M+Æ). Anal. Calcd. for C18H17Cl2N3O8S3: C 37.90, H 3.00,
N 7.37; found C 38.21, H 3.51, N 7.78.
2.4. Typical procedure for the synthesis 2-(((arylsulfonyl)
aminosulfonyl)methyl)-5-((40,50-dihydro-10,30-diphenyl-50-aryl-
10H-pyrazol-40-ylsulfonyl)methyl)-1,3,4-thiadiazole 6a–c
The compound 3 (1.0 mmol), benzaldehyde phenylhydrazone
(1.2 mmol), chloramine-T (0.33 g, 1.2 mmol) and methanol
(20 mL) were reﬂuxed for 23–25 h. The precipitated inorganic
salts were ﬁltered off. The ﬁltrate was concentrated and the
residue was extracted with dichloromethane. The organic layer
was washed with water, brine and dried (an. Na2SO4). Evapo-
ration of the solvent under reduced pressure yielded a solid
which was puriﬁed by column chromatography (silica gel,
60–120 mesh) using hexane/EtOAc (4:1) as eluent.
2.4.1. 2-(((Phenylsulfonyl)aminosulfonyl)methyl)-5-((40,
50-dihydro-10,30-diphenyl-50-phenyl-10H-pyrazol-40-ylsulfonyl)
methyl)-1,3,4-thiadiazole (6a)
Yield 73% as a pale yellow solid (0.50 g). M.p. 189–191 C. IR
(KBr): m= 3230 (NH), 1563 (C‚N), 1318, 1147 (SO2) cm
1.
1H NMR (DMSO-d6): d= 4.68 (s, 2H, CH2-(C-5)), 5.08 (s,
2H, CH2-(C-2)), 5.15 (d, 1H, C40-H, J = 7.1 Hz), 5.30 (d,
1H, C50-H, J = 7.2 Hz), 7.20–7.72 (m, 20 H, ArH), 10.42 (bs,
1H, NH) ppm. 13C NMR (DMSO-d6): d= 46.2 (CH2-(C-5)),
51.1 (CH2-(C-2)), 64.1 (C-4
0), 82.5 (C-50), 123.6, 124.3, 125.5,
126.1, 127.3, 128.2, 130.1, 131.3, 132.4, 132.8, 133.2, 133.9,
134.2, 134.8, 136.4, 138.2 (ArC), 153.4 (C-30), 155.8 (C-5),
156.8 (C-2) ppm. MS (m/z): 693.84 (M+Æ). Anal. Calcd. for
C31H27N5O6S4: C 53.66, H 3.92, N 10.09; found C 53.82, H
4.21, N 10.20.
2.4.2. 2-(((4-Methylphenylsulfonyl)aminosulfonyl)methyl)-5-
((40,50-dihydro-10,30-diphenyl-50-(4-methylphenyl)-10H-pyrazol-
40-ylsulfonyl)methyl)-1,3,4-thiadiazole (6b)
Yield 67% as a pale yellow solid (0.48 g). M.p. 204–206 C. IR
(KBr): m= 3226 (NH), 1555 (C‚N), 1311, 1135 (SO2) cm
1.
1H NMR (DMSO-d6): d= 2.19 & 2.36 (s, 6 H, Ar–CH3),
4.62 (s, 2H, CH2-(C-5)), 4.98 (s, 2H, CH2-(C-2)), 5.09 (d,
1H, C40-H, J= 6.8 Hz), 5.24 (d, 1H, C50-H, J= 6.8 Hz),
7.12–7.58 (m, 18 H, ArH), 10.38 (bs, 1H, NH) ppm. 13C
NMR (DMSO-d6): d= 21.9 & 22.3 (Ar–CH3), 45.6 (CH2-
(C-5)), 51.8 (CH2-(C-2)), 62.8 (C-4
0), 81.1 (C-50), 122.3,
123.2, 124.5, 125.5, 126.1, 126.6, 127.5, 128.4, 130.2, 131.6,
132.9, 133.2, 133.8, 134.6, 135.3, 137.4 (ArC), 151.8 (C-30),
154.1 (C-5), 155.6 (C-2) ppm. MS (m/z): 721.89 (M+Æ). Anal.
950 M.R. Guda et al.Calcd. for C33H31N5O6S4: C 54.90, H 4.32, N 9.70; found C
55.24, H 4.69, N 9.91.
2.4.3. 2-(((4-Chlorophenylsulfonyl)aminosulfonyl)methyl)-5-
((40,50-dihydro-10,30-diphenyl-50-(4-chlorophenyl)-10H-pyrazol-
40-ylsulfonyl)methyl)-1,3,4-thiadiazole (6c)
Yield 79% as a pale yellow solid (0.60 g). M.p. 218–220 C. IR
(KBr): m= 3235 (NH), 1567 (C‚N), 1327, 1151 (SO2) cm
1.
1H NMR (DMSO-d6): d= 4.79 (s, 2H, CH2-(C-5)), 5.13 (s,
2H, CH2-(C-2)), 5.22 (d, 1H, C40-H, J= 7.4 Hz), 5.33 (d,
1H, C50-H, J= 7.3 Hz), 7.25–7.72 (m, 18 H, ArH), 10.45 (bs,
1H, NH) ppm. 13C NMR (DMSO-d6): d= 47.8 (CH2-(C-5)),
52.2 (CH2-(C-2)), 66.6 (C-4
0), 84.2 (C-50), 124.4, 125.6, 126.1,
127.2, 128.8, 130.2, 131.7, 132.3, 132.9, 134.2, 135.1, 136.5,
137.2, 138.6, 139.2, 139.9 (ArC), 154.6 (C-30), 156.3 (C-5),
158.2 (C-2) ppm. MS (m/z): 762.74 (M+Æ). Anal. Calcd. for
C31H25Cl2N5O6S4: C 48.81, H 3.30, N 9.18; found C 49.01,
H 3.54, N 9.26.
2.5. Typical procedure for the synthesis of 2-(((arylsulfonyl)
aminosulfonyl)methyl)-5-((40,50-dihydro-30-phenyl-50-
arylisoxazol-40-ylsulfonyl)methyl)-1,3,4-thiadiazole 7a–c
A mixture of compound 3 (1.0 mmol), benzaldehyde oxime
(1.2 mmol), chloramine-T (0.33 g, 1.2 mmol) and methanol
(20 mL) was reﬂuxed for 17–20 h. The precipitated inorganic
salts were ﬁltered off. The ﬁltrate was concentrated and the
residue was extracted with dichloromethane. The organic layer
was washed with water, brine and dried (an. Na2SO4). The sol-
vent was removed under vacuum. The resultant residue was
puriﬁed by column chromatography (silica gel, 60–120 mesh)
using hexane/EtOAc (4:1) as eluent.
2.5.1. 2-(((Phenylsulfonyl)aminosulfonyl)methyl)-5-((40,50-
dihydro-30-phenyl-50-phenylisoxazol-40-ylsulfonyl)methyl)-1,
3,4-thiadiazole (7a)
Yield 74% as a white solid (0.45 g). M.p. 174–176 C. IR
(KBr): m= 3240 (NH), 1565 (C‚N), 1326, 1132 (SO2) cm
1.
1H NMR (DMSO-d6): d= 4.88 (s, 2H, CH2-(C-5)), 5.08 (d,
1H, C40-H, J= 7.5 Hz), 5.14 (s, 2H, CH2-(C-2)), 5.41 (d, 1H,
C50-H, J= 7.5 Hz), 7.21–7.80 (m, 15 H, ArH), 10.50 (bs, 1H,
NH) ppm. 13C NMR (DMSO-d6): d= 47.4 (CH2-(C-5)),
52.8 (CH2-(C-2)), 63.4 (C-4
0), 84.4 (C-50), 125.6, 126.4, 127.3,
128.6, 129.2, 130.4, 131.1, 132.1, 132.8, 133.6, 134.3, 136.2
(ArC), 154.2 (C-30), 156.2 (C-5), 157.4 (C-2) ppm. MS (m/z):
618.73 (M+Æ). Anal. Calcd. for C25H22N4O7S4: C 48.53, H
3.58, N 9.05; found C 48.61, H 3.72, N 9.09.
2.5.2. 2-(((4-Methylphenylsulfonyl)aminosulfonyl)methyl)-5-
((40,50-dihydro-30-phenyl-50-(4-methylphenyl)isoxazol-40-
ylsulfonyl)methyl)-1,3,4-thiadiazole (7b)
Yield 68% as a white solid (0.43 g). M.p. 196–198 C. IR
(KBr): m= 3236 (NH), 1560 (C‚N), 1321, 1124 (SO2) cm
1.
1H NMR (DMSO-d6): d= 2.26 & 2.38 (s, 6 H, Ar–CH3),
4.80 (s, 2H, CH2-(C-5)), 5.01 (d, 1H, C40-H, J= 7.1 Hz),
5.06 (s, 2H, CH2-(C-2)), 5.36 (d, 1H, C50-H, J= 7.1 Hz),
7.18–7.73 (m, 13 H, ArH), 10.47 (bs, 1H, NH) ppm. 13C
NMR (DMSO-d6): d= 22.4 & 23.9 (Ar–CH3), 46.2 (CH2-
(C-5)), 51.4 (CH2-(C-2)), 61.8 (C-4
0), 83.6 (C-50), 123.8,
124.2, 126.4, 127.2, 128.5, 129.3, 130.5, 131.1, 132.4, 133.6,
134.2, 135.4 (ArC), 152.2 (C-30), 155.6 (C-5), 156.3 (C-2)ppm. MS (m/z): 646.79 (M+Æ). Anal. Calcd. for C27H26N4O7S4:
C 50.14, H 4.05, N 8.66; found C 50.08, H 3.95, N 8.62.
2.5.3. 2-(((4-Chlorophenylsulfonyl)aminosulfonyl)methyl)-5-
((40,50-dihydro-30-phenyl-50-(4-chlorophenyl)isoxazol-40-
ylsulfonyl)methyl)-1,3,4-thiadiazole (7c)
Yield 78% as a white solid (0.53 g). M.p. 210–212 C. IR
(KBr): m= 3250 (NH), 1573 (C‚N), 1332, 1139 (SO2) cm
1.
1H NMR (DMSO-d6): d= 4.92 (s, 2H, CH2-(C-5)), 5.14 (d,
1H, C40-H, J= 7.7 Hz), 5.18 (s, 2H, CH2-(C-2)), 5.48 (d, 1H,
C50-H, J= 7.6 Hz), 7.26–7.89 (m, 13 H, ArH), 10.52 (bs, 1H,
NH) ppm. 13C NMR (DMSO-d6): d= 48.2 (CH2-(C-5)),
53.6 (CH2-(C-2)), 64.5 (C-4
0), 84.7 (C-50), 125.9, 126.4, 127.6,
128.5, 129.8, 130.4, 131.8, 133.6, 134.2, 135.3, 136.6, 137.4
(ArC), 154.9 (C-30), 157.9 (C-5), 158.8 (C-2) ppm. MS (m/z):
687.62 (M+Æ). Anal. Calcd. for C25H20Cl2N4O7S4: C 43.67,
H 2.93, N 8.14; found C 44.01, H 3.41, N 8.37.
2.6. Typical procedure for the synthesis of 2-(((arylsulfonyl)
aminosulfonyl)methyl)-5-((10,30-diphenyl-50-aryl-10H-pyrazol-
40-ylsulfonyl)methyl)-1,3,4-thiadiazole 8a–c/2-(((arylsulfonyl)
aminosulfonyl)methyl)-5-((30-phenyl-50-arylisoxazol-40-
ylsulfonyl)-methyl)-1,3,4-thiadiazole 9a–c
To a solution of compound 6/7 (1.3 mmol) in benzene (50 mL),
Manganese dioxide (MnO2) (0.43 g, 5.0 mmol) was added and
stirred for 6–8 h at room temperature. After completion of the
reaction, the reaction mixture was ﬁltered. Removal of the sol-
vent under reduced pressure resulted in a residue which was
puriﬁed by column chromatography (chloroform/EtOAc, 2:1).
2.6.1. 2-(((Phenylsulfonyl)aminosulfonyl)methyl)-5-((10,30-
diphenyl-50-phenyl-10H-pyrazol-40-ylsulfonyl)methyl)-1,3,4-
thiadiazole (8a)
Yield 86% as a white solid (0.59 g). M.p. 180–182 C. IR
(KBr): m= 3246 (NH), 1622 (C‚C), 1584 (C‚N), 1330,
1145 (SO2) cm
1. 1H NMR (DMSO-d6): d= 5.05 (s, 2H,
CH2-(C-5)), 5.28 (s, 2H, CH2-(C-2)), 7.12–7.76 (m, 20 H,
ArH), 10.58 (bs, 1H, NH) ppm. 13C NMR (DMSO-d6):
d= 45.4 (CH2-(C-5)), 48.9 (CH2-(C-2)), 122.7, 123.8, 124.2,
125.9, 126.4, 127.3, 128.6, 129.2, 130.4, 131.7, 132.4, 133.5,
134.1, 135.8, 136.4, 137.2 (ArC), 137.8 (C-40), 144.2 (C-30),
147.2 (C-50), 153.1 (C-5), 154.6 (C-2) ppm. MS (m/z): 691.83
(M+Æ). Anal. Calcd. for C31H25N5O6S4: C 53.81, H 3.64, N
10.12; found C 53.86, H 3.71, N 10.47.
2.6.2. 2-(((4-Methylphenylsulfonyl)aminosulfonyl)methyl)-
5-((10,30-diphenyl-50-(4-methylphenyl)-10H-pyrazol-40-
ylsulfonyl)methyl)-1,3,4-thiadiazole (8b)
Yield 83% as a white solid (0.58 g). M.p. 193–195 C. IR
(KBr): m= 3238 (NH), 1615 (C‚C), 1572 (C‚N), 1324,
1138 (SO2) cm
1. 1H NMR (DMSO-d6): d= 2.20 & 2.34 (s,
6 H, Ar–CH3), 5.01 (s, 2H, CH2-(C-5)), 5.20 (s, 2H, CH2-(C-
2)), 7.06–7.54 (m, 18 H, ArH), 10.54 (bs, 1H, NH) ppm. 13C
NMR (DMSO-d6): d= 21.4 & 22.6 (Ar–CH3), 44.8 (CH2-
(C-5)), 49.6 (CH2-(C-2)), 122.1, 122.9, 123.4, 124.3, 125.5,
125.9, 126.4, 127.2, 128.6, 129.3, 130.6, 132.7, 133.2, 134.6,
135.4, 136.2 (ArC), 136.4 (C-40), 142.6 (C-30), 145.4 (C-50),
152.8 (C-5), 155.2 (C-2) ppm. MS (m/z): 719.88 (M+Æ). Anal.
Calcd. for C33H29N5O6S4: C 55.05, H 4.06, N 9.72; found C
55.34, H 4.09, N 10.01.
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5-((10,30-diphenyl-50-(4-chlorophenyl)-10H-pyrazol-40-
ylsulfonyl)methyl)-1,3,4-thiadiazole (8c)
Yield 88% as a white solid (0.66 g). M.p. 225–227 C. IR
(KBr): m= 3254 (NH), 1626 (C‚C), 1590 (C‚N), 1335,
1149 (SO2) cm
1. 1H NMR (DMSO-d6): d= 5.11 (s, 2H,
CH2-(C-5)), 5.32 (s, 2H, CH2-(C-2)), 7.22–7.94 (m, 18 H,
ArH), 10.60 (bs, 1H, NH) ppm. 13C NMR (DMSO-d6):
d= 46.2 (CH2-(C-5)), 50.4 (CH2-(C-2)), 124.3, 124.6, 125.9,
126.3 127.6 128.5, 129.8, 130.5, 131.6 132.3, 133.6, 134.2,
135.4, 136.6, 137.2, 138.1 (ArC), 138.6 (C-40), 146.3 (C-30),
149.6 (C-50), 153.8 (C-5), 157.8 (C-2) ppm. MS (m/z): 760.72
(M+Æ). Anal. Calcd. for C31H23 Cl2N5O6S4: C 48.94, H 3.04,
N 9.21; found C 49.15, H 3.37, N 9.08.
2.6.4. 2-(((Phenylsulfonyl)aminosulfonyl)methyl)-5-
((30-phenyl-50-phenylisoxazol-40-ylsulfonyl)methyl)-1,3,
4-thiadiazole (9a)
Yield 85% as a white solid (0.52 g). M.p. 186–188 C. IR
(KBr): m= 3256 (NH), 1642 (C‚C), 1580 (C‚N), 1342,
1160 (SO2) cm
1. 1H NMR (DMSO-d6): d= 5.28 (s, 2H,
CH2-(C-5)), 5.39 (s, 2H, CH2-(C-2)), 7.30–7.82 (m, 15 H,
ArH), 10.62 (bs, 1H, NH) ppm. 13C NMR (DMSO-d6):
d= 46.8 (CH2-(C-5)), 50.6 (CH2-(C-2)), 125.7, 126.2, 127.4,
128.8, 129.2, 131.4, 132.8, 133.5, 134.2, 135.6, 136.1, 136.8
(ArC), 138.2 (C-40), 145.6 (C-30), 150.2 (C-50), 155.2 (C-5),
156.1 (C-2) ppm. MS (m/z): 616.72 (M+Æ). Anal. Calcd. for
C25H20N4O7S4: C 48.68, H 3.26, N 9.08; found C 48.83, H
3.84, N 9.22.
2.6.5. 2-(((4-Methylphenylsulfonyl)aminosulfonyl)methyl)-
5-((30-phenyl-50-(4-methylphenyl)isoxazol-40-ylsulfonyl)
methyl)-1,3,4-thiadiazole (9b)
Yield 82% as a white solid (0.52 g). M.p. 197–199 C. IR
(KBr): m= 3252 (NH), 1638 (C‚C), 1582 (C‚N), 1335,
1152 (SO2) cm
1. 1H NMR (DMSO-d6): d= 2.24 & 2.41 (s,
6 H, Ar–CH3), 5.16 (s, 2H, CH2-(C-5)), 5.35 (s, 2H, CH2-(C-
2)), 7.22–7.71 (m, 13 H, ArH), 10.55 (bs, 1H, NH) ppm. 13C
NMR (DMSO-d6): d= 22.1 & 23.4 (Ar–CH3), 44.6 (CH2-
(C-5)), 50.2 (CH2-(C-2)), 124.5, 125.2, 126.4, 127.8, 128.7,
129.4, 130.6, 132.9, 133.4, 134.2, 135.6, 136.2 (ArC), 137.6
(C-40), 143.5 (C-30), 149.4 (C-50), 154.4 (C-5), 155.8 (C-2)
ppm. MS (m/z): 644.77 (M+Æ). Anal. Calcd. for C27H24N4O7-
S4: C 50.29, H 3.75, N 8.68; found C 50.38, H 3.61, N 8.74.
2.6.6. 2-(((4-Chlorophenylsulfonyl)aminosulfonyl)methyl)
-5-((30-phenyl-50-(4-chlorophenyl)isoxazol-40-ylsulfonyl)
methyl)-1,3,4-thiadiazole (9c)
Yield 90% as a white solid (0.61 g). M.p. 206–208 C. IR
(KBr): m= 3260 (NH), 1651 (C‚C), 1585 (C‚N), 1350,O
NHNH2Ar
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1. 1H NMR (DMSO-d6): d= 5.37 (s, 2H,
CH2-(C-5)), 5.45 (s, 2H, CH2-(C-2)), 7.28–7.89 (m, 13 H,
ArH), 10.64 (bs, 1H, NH) ppm. 13C NMR (DMSO-d6):
d= 47.2 (CH2-(C-5)), 51.6 (CH2-(C-2)), 126.7, 127.4, 128.2,
129.6, 130.3, 131.9, 133.2, 134.8, 135.4, 136.2, 137.6, 138.1
(ArC), 138.8 (C-40), 147.2 (C-30), 152.6 (C-50), 155.9 (C-5),
156.8 (C-2) ppm. MS (m/z): 685.61 (M+Æ). Anal. Calcd. for
C25H18Cl2N4O7S4: C 43.80, H 2.64, N 8.17; found C 44.31,
H 2.92, N 8.39.3. Results and discussion
The bis heterocycles, pyrazolyl and isoxazolyl 1,3,4-thiadiaz-
oles were synthesized from the synthetic intermediate
2-(((arylsulfonyl)aminosulfonyl)methyl)-5-[Z-(styrylsulfonyl)
methyl]-1,3,4-thiadiazole (3). The compound 3 was prepared in
different routes in order to optimize the yield. Earlier 1,3,
4-thiadiazole moiety was built by the exchange of oxygen atom
in oxadiazole with sulfur (Padmaja et al., 2012). However this
transformation failed when 2-(((arylsulfonyl)aminosulfo-
nyl)methyl)-5-((styrylsulfonyl)methyl)-1,3,4-oxadiazole was
treated with thiourea. In order to prepare compound 3, initially
one-pot reaction of 2-((phenylsulfonyl)aminosulfonyl)acet-
ohydrazide (1a) and Z-styrylsulfonylacetic acid (2a) with P2S5
in the presence of T3P and TEA in equimolar ratio was carried
out (Scheme 1). After heating for 5 h, the product 2-(((phenyl-
sulfonyl)aminosulfonyl)methyl)-5-[Z-(styrylsulfonyl)methyl]-
1,3,4-thiadiazole (3a) was isolated in 35% yield along with the
by product 2-(((phenylsulfonyl)aminosulfonyl)methyl)-5-[Z-
(styrylsulfonyl)methyl]-1,3,4-oxadiazole (4a) in 20% yield. In
the literature, it was reported that the reaction of 1 equivalent
of 4-toluic acid and 3-ﬂuorophenylhydrazide with 1.5 equiva-
lents of P2S5 in the presence of 1.2 equivalents of T3P and 2.5
equivalents of TEA gave the desired 1,3,4-thiadiazole in 92%
yield (Augustine et al., 2009). Employing similar reaction con-
ditions, we repeated the reaction of 1a and 2a with 1.5 equiva-
lents of P2S5, 1.2 equivalents of T3P and 2.5 equivalents of TEA
but there was no appreciable increase in the yield of compound
3 (Table 1). Later a two-step route via benzohydrazide followed
by cyclization was adopted. The hydrazide, N0-(2-((arylsulfo-
nyl)aminosulfonyl)acetyl)-2-(styrylsulfonyl)acetohydrazide (5)
was prepared by the reaction of 1 with 2 in the presence of
HATU and DIPEA in DMF. The compound 5 was obtained
in almost quantitative yields. The compound 5a was heated
with 1.5 equivalents of LR in EtOAc for 8 h. The product 3a
was formed in 55% along with 1,3,4-oxadiazole (4a) in 19%
yield (Method A). However, when the same reaction was per-
formed with 1.5 equivalents of LR, 1.2 equivalents of T3P
and 2.5 equivalents of TEA compound 3a was obtained in
85% yield along with a minor amount of 4a in 2% yieldS
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Table 1 Comparison of yields in different equivalents of reagents.
Entry Reagent (equivalents) Ar Product 3 Product 4
P2S5:T3P:TEA Yield (%) mp (C) Yield (%) mp (C)
1 1:1:1 C6H5 35 157–159 20 128–130
2 1.5:1.2:2.5 C6H5 39 157–159 18 128–130
3 1.5:1.2:2.5 4-Me C6H4 36 135–137 23 115–117
4 1.5:1.2:2.5 4-Cl C6H4 38 171–173 21 139–141
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Scheme 2 Two-step synthesis of 1,3,4-thiadiazoles.
Table 2 Comparison of yields in Method A and Method B.
Entry Ar Method A, Yield (%) Method B, Yield (%)
Product 3 Product 4 Product 3 Product 4
1 C6H5 55 19 85 2
2 4-Me C6H4 52 14 90 2
3 4-Cl C6H4 49 16 88 3
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Table 3 Yields of compounds 6–9.
Entry Compound Yield Entry Compound Yield
1 6a 73 7 8a 86
2 6b 67 8 8b 83
3 6c 79 9 8c 88
4 7a 74 10 9a 85
5 7b 68 11 9b 82
6 7c 78 12 9c 90
An efﬁcient synthesis of styryl 1,3,4-thiadiazoles 953(Method B). Adopting similar methodology, the compounds 3b
and 3c were prepared (Scheme 2 and Table 2).
The (3+2) p 1,3-dipolar cycloaddition reaction of dipolar
reagents to Michael acceptors is a simple and a facile technique
to prepare ﬁve-membered heterocycles. The oleﬁn moiety
present in compound 3 was exploited to synthesize pyrazoles
and isoxazoles by cycloaddition of dipolar reagents––nitrile
imines and nitrile oxides. Thus, 2-(((arylsulfonyl)amino-sulfo-
nyl)methyl)-5-((40,50-dihydro-10,30-diphenyl-50-aryl-10H-pyrazol
-40-ylsulfonyl)methyl)-1,3,4-thiadiazole (6) and 2-(((arylsulfo-
nyl)amino-sulfonyl)methyl)-5-((40,50-dihydro-30-phenyl-50-aryl-
isoxazol-40-ylsulfonyl)methyl)-1,3,4-thiadiazole (7) were
prepared by cycloaddition of nitrile imine and nitrile oxide
generated from benzaldehyde phenylhydrazone and ben-
zaldoxime in the presence of chloramine-T to 3 (Scheme 3).
In 1,2-disubstituted ethylenes bearing two vicinal electron
withdrawing substituents a regioisomeric mixture of cycload-
ducts is expected. However, the reaction of 1-aryl-2-aroylethyl-
enes with diazomethane and its derivatives produced
exclusively 3-aroyl-4-aryl-2-pyrazolines (Bhaskar Reddy
et al., 1986). Similarly, the cycloaddition of nitrile imines and
nitrile oxides to 1,4-bis-((E)-2(aroylsulfonyl)vinyl)benzene
gave pyrazolines and isoxazolines. In the present study, the
addition of nitrile imines and nitrile oxides to 3 resulted in only
one pure regioisomer 6 and 7 respectively. A small amount of
the other isomer if any, formed could not be isolated by this
process. There are several methods for oxidation of pyrazo-
lines and isoxazolines to the corresponding aromatized prod-
ucts (Padmaja et al., 2011a,b; Srivastava et al., 2003). We
focused our attention toward the transformation of pyrazo-
lines and isoxazolines to pyrazoles and isoxazoles adopting
the oxidation protocol using activated MnO2 to achieve better
yields. In fact, the oxidation of compounds 6 and 7 with MnO2
in benzene led to the formation of 2-(((arylsulfonyl)amin-
osulfonyl)methyl)-5-((10,30-diphenyl-50-aryl-10H-pyrazol-40-
ylsulfonyl)methyl)-1,3,4-thiadiazole (8)/2-(((arylsulfonyl)amin-
osulfonyl)meth-yl)-5-((30-phenyl-50-arylisoxazol-40-ylsulfonyl)
methyl)-1,3,4-thiadiazole (9) in 80–90% yield (Table 3). All the
new compounds (3, 5, 6–9) were characterized by IR, 1H
NMR, 13C NMR, mass and elemental analyses.
4. Conclusion
The compounds styryl 1,3,4-thiadiazoles were prepared from
different routes to optimize the yield of the products. The two-
step methodology via benzohydrazide followed by treatment
with Lawesson’s reagent in the presence of Propylphosphonic
anhydride and triethylamine produced styryl 1,3,4-thiadiazoles
in excellent yields. The oleﬁn moiety in these compounds is uti-
lized to develop pyrazole and isoxazole rings by 1,3-dipolar
cycloaddition methodology followed by oxidation.Acknowledgments
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